# Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

> **NCT04802876** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 184 (estimated)

## Conditions studied

- MSI-H Colorectal Cancer
- Melanoma
- Anal Carcinoma
- Mesothelioma
- Triple Negative Breast Cancer
- Lung Adenocarcinoma
- Cholangiocarcinoma
- Cervical Carcinoma
- Kidney Clear Cell Carcinoma
- Stomach Adenocarcinoma
- Esophageal Adenocarcinoma
- Uterine Adenocarcinoma
- Head and Neck Squamous Cell Carcinoma
- Sarcoma
- Lung Squamous Cell Carcinoma
- Urothelial Carcinoma
- Thyroid Carcinoma
- Hepatocellular Carcinoma
- Uveal Melanoma
- HER2-positive Breast Cancer
- Pancreatic Adenocarcinoma
- Squamous Esophageal Carcinoma
- Epithelial Ovarian Cancer
- Uterine Carcinosarcoma
- Small Cell Lung Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation
- Colorectal Adenocarcinoma
- Prostate Adenocarcinoma
- Carcinoma of Unknown Primary
- Other Histology

## Interventions

- **DRUG:** Spartalizumab
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT04802876
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-12
- **Primary completion:** 2025-09-30
- **Final completion:** 2027-03-31
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04802876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04802876, "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04802876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*